Carterra

Summary

Carterra builds high-throughput surface plasmon resonance (SPR) instruments — chiefly the LSA family and newer Vega/Ultra platforms — for monoclonal-antibody discovery and characterization. Antibody therapeutics depend on knowing how candidates bind — kinetics, affinity, and epitope diversity — early enough to choose the right clones from large libraries.

Impact

Antibody therapeutics depend on knowing how candidates bind — kinetics, affinity, and epitope diversity — early enough to choose the right clones from large libraries. Carterra's instruments sit in that characterization step. The company's 2017 release describes array-based SPRi detection coupled to microfluidics for high-throughput mAb library screening (rename announcement).

Independent of company copy, a 2020 PLOS ONE industry collaboration measured anti-PD-1 antibody binding kinetics on a Carterra LSA and compared results to a Biacore 8K, reporting near-identical rate and affinity constants on flat sensor chips and using the LSA for epitope binning across the panel (PD-1 landscape paper). That paper is evidence the platform is used in pharmaceutical antibody-characterization work, not merely sold for it — though it validates one instrument class in one therapeutic area, not market share.

Bet: that making SPR truly high-throughput — hundreds of parallel interactions per run — shifts antibody discovery from triaging a few clones to characterizing whole libraries, and that the bottleneck moved from "can we measure binding?" to "can we measure all of them?"

The honest counterweight: this is a tools vendor to drug discovery, not a therapeutic developer; impact is indirect and concentrated in labs that can afford specialized biosensor platforms. No third-party measure of how widely deployed Carterra systems are appears in the captured sources.

Utah Context

Carterra is a documented University of Utah spinout lineage: campus formation in 2004, Lassonde commercialization programs, and continued Salt Lake City headquarters on the company's own site. It connects the wiki's health-bio instrument makers to the U's mechanical-engineering and entrepreneurship pipeline.

What They Need Now

The company's homepage and careers navigation point to instrument sales, applications support, and software for kinetics and epitope analysis — roles spanning biophysics applications scientists, microfluidics and optical hardware engineers, and software for high-throughput biosensor data (official site). Specific open requisitions were not captured here.

Open Questions

• No corporate identifier resolved. No utah-entity, ein, or SEC record has been pulled; a Utah Division of Corporations search could confirm the Wasatch Microfluidics → Carterra legal-entity continuity and incorporation date.
• Founding year conflict. The 2017 company release says founded 2005; the Lassonde profile describes campus formation in 2004. Both may be true (idea/team vs incorporation) but the wiki does not have a registry record to reconcile them.
• Market position is unverified. Superlatives on the company site ("highest-throughput SPR platforms on the market") are self-reported. The peer-reviewed source validates instrument use in one study; it does not establish share of pharma antibody-screening labs.
• Headcount and revenue are not stated on the captured homepage.

Evidence

• Source: Carterra Official Website · https://carterra-bio.com/
• Source: Wasatch Microfluidics Announces Name Change to Carterra (2017) · https://carterra-bio.com/news/wasatch-microfluidics-announces-name-change-to-carterra-inc-and-new-high-throughput-spr-instrument/
• Source: Lassonde — Wasatch Microfluidics Profile · https://lassonde.utah.edu/wasatch-microfluidics-from-the-lassonde-institute-to-pfizer-research-offices/
• Source: Assessing the Binding Properties of the anti-PD-1 Antibody Landscape (2020) · https://doi.org/10.1371/journal.pone.0229206